Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of lesigercept in adults with chronic spontaneous urticaria inadequately controlled by H1-antihistamines
jRCT2031260326Phase 2Recruiting
- Sponsor
- Maruho Co., Ltd.
- Start
- Jul 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
01
Overview
Phase 2, randomised trial in chronic idiopathic urticaria (CIU) comparing Lesigercept with Placebo (2 arms). Primary endpoint: Change from baseline in UAS7 at Week 12. Started Jul 2026; status: recruiting.
02
Drugs
YH35324
03
Conditions
chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on jRCT2031260326.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260326.